{
    "meeting_annotations": [
        {
            "speaker": "Noah Palm",
            "timestamp": "00:00-00:16",
            "transcript": "and picking, you know, like so for Parkinson's disease um, uh you may use something like constipation as a sign of potential prodromal Parkinsons. Then you design a large cohort of people that fit that characteristic, collect as early on as when they show that particular set of biomarkers.",
            "speaking_duration": 16,
            "nods_others": 2,
            "smile_self": 25,
            "smile_other": 0,
            "distracted_others": 0,
            "hand_gesture": "None",
            "interuption": "No",
            "overlap": "No",
            "screenshare": "No",
            "screenshare_content": "None"
        },
        {
            "speaker": "Noah Palm",
            "timestamp": "00:16-00:22",
            "transcript": "um, uh and um and you work your way back from there. See basically what's the earliest you can get uh uh yeah, get a signal",
            "speaking_duration": 6,
            "nods_others": 0,
            "smile_self": 60,
            "smile_other": 0,
            "distracted_others": 0,
            "hand_gesture": "None",
            "interuption": "No",
            "overlap": "No",
            "screenshare": "No",
            "screenshare_content": "None"
        },
        {
            "speaker": "Noah Palm",
            "timestamp": "00:22-00:36",
            "transcript": "um uh from those populations. Yeah, again, I I I don't work really in this biomarker field at all, but it does feel like there's got to be some way of working backwards and obviously having just really big cohorts of all the data at from birth on is one way to do it. That's what",
            "speaking_duration": 14,
            "nods_others": 0,
            "smile_self": 40,
            "smile_other": 0,
            "distracted_others": 0,
            "hand_gesture": "Open Palms",
            "interuption": "No",
            "overlap": "No",
            "screenshare": "No",
            "screenshare_content": "None"
        },
        {
            "speaker": "Noah Palm",
            "timestamp": "00:36-01:16",
            "transcript": "you know, they're better at doing that in Europe, Scandinavia, etc than we are here. I think from from what I've seen. Um, but in lieu of that, um, you know, maybe trying to work your way backwards with guessing at people who are eventually going to develop the disease based on marker X and then developing a slightly better guess that allows you to work your way a little bit backwards in years um iteratively.",
            "speaking_duration": 40,
            "nods_others": 1,
            "smile_self": 60,
            "smile_other": 0,
            "distracted_others": 0,
            "hand_gesture": "Open Palms",
            "interuption": "No",
            "overlap": "No",
            "screenshare": "No",
            "screenshare_content": "None"
        },
        {
            "speaker": "Carolina Tropini",
            "timestamp": "01:16-02:09",
            "transcript": "I think that's a really good point about the the timing component and the I think for the microbiome field, one of the challenges is that the effects happen after such a long period of time. And if we're looking at even neurodegenerative diseases, it's I think that it's very restrictive to only look at the aging population for this because likely the effects of the microbiota will be happening over decades. And so that presents a challenge, but also an opportunity to set up systems that will fund research that can really span an entire lifetime.",
            "speaking_duration": 53,
            "nods_others": 2,
            "smile_self": 10,
            "smile_other": 0,
            "distracted_others": 0,
            "hand_gesture": "None",
            "interuption": "No",
            "overlap": "No",
            "screenshare": "No",
            "screenshare_content": "None"
        },
        {
            "speaker": "Carolina Tropini",
            "timestamp": "02:05-02:09",
            "transcript": "and and also here, you know, the study design becomes really important, of course, because you you want to be following people for a really long time so that some of these microbiota effects can become evident.",
            "speaking_duration": 4,
            "nods_others": 0,
            "smile_self": 20,
            "smile_other": 0,
            "distracted_others": 0,
            "hand_gesture": "None",
            "interuption": "No",
            "overlap": "No",
            "screenshare": "No",
            "screenshare_content": "None"
        },
        {
            "speaker": "Calvin Ye",
            "timestamp": "02:10-02:23",
            "transcript": "Yeah, and I think that kind of data set follow a large number of individuals for for their lifetime, keep check of electronic health record or the biomarker. That's my dream data set.",
            "speaking_duration": 13,
            "nods_others": 0,
            "smile_self": 20,
            "smile_other": 0,
            "distracted_others": 0,
            "hand_gesture": "Open Palms",
            "interuption": "No",
            "overlap": "No",
            "screenshare": "No",
            "screenshare_content": "None"
        },
        {
            "speaker": "Calvin Ye",
            "timestamp": "02:23-02:40",
            "transcript": "And right now we have look at those data set not the same, but we have similar data set UK Bank 50,000 individuals, electronic health record a lot of data, but they do not have microbiome. So so ideally we start a cohort, follow them for a long time.",
            "speaking_duration": 17,
            "nods_others": 0,
            "smile_self": 40,
            "smile_other": 0,
            "distracted_others": 0,
            "hand_gesture": "Open Palms",
            "interuption": "No",
            "overlap": "No",
            "screenshare": "No",
            "screenshare_content": "None"
        },
        {
            "speaker": "Calvin Ye",
            "timestamp": "02:40-03:05",
            "transcript": "And there there's one possibility to help us narrow down the the the participant. We can use genetic data to predict who has a higher risk for specific uh neurodegenerative disease and that can help us focus on people that are predicted to have higher risk. Can reduce the sample size a little bit? I just an idea.",
            "speaking_duration": 25,
            "nods_others": 0,
            "smile_self": 20,
            "smile_other": 0,
            "distracted_others": 0,
            "hand_gesture": "Open Palms",
            "interuption": "No",
            "overlap": "No",
            "screenshare": "No",
            "screenshare_content": "None"
        },
        {
            "speaker": "Noah Palm",
            "timestamp": "03:06-03:32",
            "transcript": "I would almost argue though the opposite, which is that really what you want to get the strongest signal are the people who have no genetic predisposition. But uh regardless of that, end up actually getting Alzheimer's, which would suggest that they have a stronger actually environmental or microbial component. And the people who are have genetically predisposed would actually have a weaker signal for non-genetic biomarkers.",
            "speaking_duration": 26,
            "nods_others": 0,
            "smile_self": 30,
            "smile_other": 20,
            "distracted_others": 0,
            "hand_gesture": "None",
            "interuption": "No",
            "overlap": "No",
            "screenshare": "No",
            "screenshare_content": "None"
        },
        {
            "speaker": "Noah Palm",
            "timestamp": "03:32-03:34",
            "transcript": "because they would need less. Yeah.",
            "speaking_duration": 2,
            "nods_others": 0,
            "smile_self": 50,
            "smile_other": 0,
            "distracted_others": 0,
            "hand_gesture": "None",
            "interuption": "No",
            "overlap": "Yes",
            "screenshare": "No",
            "screenshare_content": "None"
        },
        {
            "speaker": "Heather Bean",
            "timestamp": "03:35-04:05",
            "transcript": "But there might be a really strong signal in the people who are genetically predisposed but do not develop the disease. Yeah. You mean for a protective biomarker? Yeah, and and maybe the protective biomarker doesn't, you know, really work, um, for predicting disease, but that might kind of, um, split the difference on being able to narrow down a target population and then still be able to find a strong signal.",
            "speaking_duration": 30,
            "nods_others": 0,
            "smile_self": 30,
            "smile_other": 0,
            "distracted_others": 0,
            "hand_gesture": "Open Palms",
            "interuption": "No",
            "overlap": "No",
            "screenshare": "No",
            "screenshare_content": "None"
        },
        {
            "speaker": "Calvin Ye",
            "timestamp": "04:06-04:21",
            "transcript": "The the key here is that you need to think about at the end, how many of the subject will develop the outcome so that you have enough sample size for you to test. Although we start with a higher risk cohort, not all of them will develop the outcome. It just a higher risk.",
            "speaking_duration": 15,
            "nods_others": 0,
            "smile_self": 0,
            "smile_other": 0,
            "distracted_others": 0,
            "hand_gesture": "Raising Hand",
            "interuption": "No",
            "overlap": "No",
            "screenshare": "No",
            "screenshare_content": "None"
        },
        {
            "speaker": "Calvin Ye",
            "timestamp": "04:21-04:34",
            "transcript": "And then by looking them like just help us reduce the sample size at the beginning, but still able to achieve enough sample size at the end.",
            "speaking_duration": 13,
            "nods_others": 0,
            "smile_self": 20,
            "smile_other": 0,
            "distracted_others": 0,
            "hand_gesture": "Raising Hand",
            "interuption": "No",
            "overlap": "No",
            "screenshare": "No",
            "screenshare_content": "None"
        },
        {
            "speaker": "George Weinstock",
            "timestamp": "04:35-04:56",
            "transcript": "Let me just also mention though, let's not totally focus on neurodegenerative diseases, right? I mean, there's autism for little kids, there's addiction, there's um schizophrenia, there's there's all kinds of other mental health conditions that are not necessarily things that you have to wait uh the whole lifetime for.",
            "speaking_duration": 21,
            "nods_others": 0,
            "smile_self": 0,
            "smile_other": 0,
            "distracted_others": 0,
            "hand_gesture": "None",
            "interuption": "No",
            "overlap": "No",
            "screenshare": "No",
            "screenshare_content": "None"
        },
        {
            "speaker": "Heather Bean",
            "timestamp": "04:56-04:58",
            "transcript": "Depression.",
            "speaking_duration": 2,
            "nods_others": 0,
            "smile_self": 0,
            "smile_other": 0,
            "distracted_others": 0,
            "hand_gesture": "None",
            "interuption": "No",
            "overlap": "Yes",
            "screenshare": "No",
            "screenshare_content": "None"
        },
        {
            "speaker": "George Weinstock",
            "timestamp": "04:57-05:00",
            "transcript": "Depression, right?",
            "speaking_duration": 3,
            "nods_others": 0,
            "smile_self": 0,
            "smile_other": 0,
            "distracted_others": 0,
            "hand_gesture": "None",
            "interuption": "No",
            "overlap": "No",
            "screenshare": "No",
            "screenshare_content": "None"
        }
    ]
}